ArticleBMC pregnancy and childbirth2025
Possible relationships between placenta and serum asprosin levels and pregnancy and spontaneous preterm births.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveAsprosin, a newly characterised adipokine, has been implicated in several physiological and pathological pathways. This study aimed to explore the association between serum and placental asprosin concentrations and the occurrence of preterm births by evaluating their potential as predictive biomarkers.
methodsA total of 75 participants were enrolled in this cross-sectional study and categorised into four groups - early preterm (delivery before 34 weeks, n = 15), late preterm (34-37 weeks, n = 15), term delivery (37-42 weeks, n = 30) and nonpregnant controls (n = 15). Serum samples were collected from all individuals, and placental tissues were obtained postdelivery from pregnant participants. Asprosin concentrations were quantified using ELISA, and correlation analyses were conducted to determine associations with clinical variables.
resultsSignificantly elevated asprosin levels were detected in both the serum and placental samples of women with preterm births compared to term deliveries (p = 0.008 for placental samples, p = 0.001 for serum samples). The highest levels were noted in the early preterm group (placental: 18.88 ± 2.12 ng/ml; serum: 19.04 ± 3.15 ng/ml). Strong inverse correlations were identified between asprosin levels and gestational age (placental: r = -0.647, p = 0.01; serum: r = -0.716, p = 0.01) and between serum asprosin and neonatal birth weight (r = -0.683, p = 0.01). The ROC analysis indicated cutoff values of 16.58 ng/ml (placenta) and 15.22 ng/ml (serum) as potential thresholds for preterm birth prediction.
conclusionIncreased maternal serum and placental asprosin levels are linked to preterm birth, demonstrating inverse associations with gestational duration and infant birth weight. These results suggest a potential role for asprosin as a predictive biomarker for preterm birth, warranting further mechanistic investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.